Efgartigimod SC is the first-approved FcRn blocker globally and is marketed as VYVGART® Hytrulo in the United States and China for the treatment of generalized myasthenia gravis (gMG) and chronic ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Jason Eagle was enjoying his time in the U.S. Navy when, about a decade ago, he realized something was off. He started to experience numbness in his leg, lost sensation in his hands and developed ...

Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Dianthus Therapeutics in a research ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...

China’s medicines regulator has granted the nod for the treatment of people with chronic inflammatory demyelinating ...

Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.

The Amsterdam-based firm markets Vyvgart, a prescription medicine indicated for neurological conditions, generalized ...